Analysis of Syndecan-2 Methylation in Bowel Lavage Fluid for the Detection of Colorectal Neoplasm
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Syndecan-2 (SDC2 ) methylation was previously reported as a sensitive serologic biomarker for the early detection of colorectal cancer (CRC). The purpose of this study was to investigate whether SDC2 methylation is detectable in precancerous lesions and to determine the feasibility of using SDC2 methylation for the detection of CRC and precancerous lesions in bowel lavage fluid (BLF). Methods: A total of 190 BLF samples were collected from the rectum at the beginning of colonoscopy from patients with colorectal neoplasm and healthy normal individuals. Fourteen polypectomy specimens were obtained during colonoscopy. A bisulfite pyrosequencing assay and quantitative methylation-specific polymerase chain reaction were conducted to measure SDC2 methylation in tissues and BLF DNA. Results: SDC2 methylation was positive in 100% of villous adenoma (VA) and high-grade dysplasia, and hyperplastic polyp samples; 88.9% of tubular adenoma samples; and 0% of normal mucosa samples. In the BLF DNA test for SDC2 methylation, the sensitivity for detecting CRC and VA was 80.0% and 64.7%, respectively, at a specificity of 88.9%. The BLF of patients with multiple tubular adenomas, single tubular adenoma and hyperplastic polyps showed 62.8%, 26.7% and 28.6% rates of methylation-positive SDC2, respectively. Conclusions: Our results demonstrated that SDC2 methylation was a frequent event in precancerous lesions and showed high potential in BLF for detecting patients with colorectal neoplasm.
Abstract
Background/Aims: Syndecan-2 (SDC2 ) methylation was previously reported as a sensitive serologic biomarker for the early detection of colorectal cancer (CRC). The purpose of this study was to investigate whether SDC2 methylation is detectable in precancerous lesions and to determine the feasibility of using SDC2 methylation for the detection of CRC and precancerous lesions in bowel lavage fluid (BLF). Methods: A total of 190 BLF samples were collected from the rectum at the beginning of colonoscopy from patients with colorectal neoplasm and healthy normal individuals. Fourteen polypectomy specimens were obtained during colonoscopy. A bisulfite pyrosequencing assay and quantitative methylation-specific polymerase chain reaction were conducted to measure SDC2 methylation in tissues and BLF DNA. Results: SDC2 methylation was positive in 100% of villous adenoma (VA) and high-grade dysplasia, and hyperplastic polyp samples; 88.9% of tubular adenoma samples; and 0% of normal mucosa samples. In the BLF DNA test for SDC2 methylation, the sensitivity for detecting CRC and VA was 80.0% and 64.7%, respectively, at a specificity of 88.9%. The BLF of patients with multiple tubular adenomas, single tubular adenoma and hyperplastic polyps showed 62.8%, 26.7% and 28.6% rates of methylation-positive SDC2, respectively. Conclusions: Our results demonstrated that SDC2 methylation was a frequent event in precancerous lesions and showed high potential in BLF for detecting patients with colorectal neoplasm.
참고문헌 (34)
- Jemal A, "Cancer statistics, 2010", CA Cancer J Clin, 60, pp.277~300 (2010)[DOI]
- Meissner HI, "Patterns of colorectal cancer screening uptake among men and women in the United States", Cancer Epidemiol Biomarkers Prev, 15, pp.389~394 (2006)[DOI]
- Ahluwalia IB, "Statespecific prevalence of selected chronic disease-related characteristics: Behavioral Risk Factor Surveillance System, 2001", MMWR Surveill Summ, 52, pp.1~80 (2003)
- Duffy MJ, "Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines", Eur J Cancer, 39, pp.718~727 (2003)[DOI]
- Harada T, "Analysis of DNA methylation in bowel lavage fluid for detection of colorectal cancer", Cancer Prev Res (Phila), 7, pp.1002~1010 (2014)[DOI]
- Kamimae S, "Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors", Cancer Prev Res (Phila), 4, pp.674~683 (2011)[DOI]
- Oh T, "Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer", J Mol Diagn, 15, pp.498~507 (2013)[DOI]
- Dejeux E, "Identification and quantification of differentially methylated loci by the pyrosequencing technology", Methods Mol Biol, 507, pp.189~205 (2009)
- Tsiatis AC, "Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications", J Mol Diagn, 12, pp.425~432 (2010)[DOI]
- Dickson G, "The prevalence of colorectal adenomas in Maori and New Zealand Europeans parallels colorectal cancer rates", N Z Med J, 123, pp.45~49 (2010)
- U.S. Preventive Services Task Force, "Screening for colorectal cancer: recommendation and rationale", Ann Intern Med, 137, pp.129~131 (2002)[DOI]
- Park DI, "Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening", Am J Gastroenterol, 105, pp.2017~2025 (2010)[DOI]
- Rozen P, "Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use", Cancer, 116, pp.2115~2125 (2010)
- Smith RA, "American Cancer Society guidelines for the early detection of cancer, 2003", CA Cancer J Clin, 53, pp.27~43 (2003)[DOI]
- Winawer SJ, "A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group", N Engl J Med, 342, pp.1766~1772 (2000)[DOI]
- Ouyang DL, "Noninvasive testing for colorectal cancer: a review", Am J Gastroenterol, 100, pp.1393~1403 (2005)[DOI]
- Fearon ER, "A genetic model for colorectal tumorigenesis", Cell, 61, pp.759~767 (1990)[DOI]
- Itzkowitz SH, "Improved fecal DNA test for colorectal cancer screening", Clin Gastroenterol Hepatol, 5, pp.111~117 (2007)[DOI]
- Boynton KA, "DNA integrity as a potential marker for stool-based detection of colorectal cancer", Clin Chem, 49, pp.1058~1065 (2003)[DOI]
- Dietmaier W, "Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression", Cancer Res, 57, pp.4749~4756 (1997)
- Losi L, "Kras and p53 mutations in human colorectal aberrant crypt foci", J Pathol, 178, pp.259~263 (1996)[DOI]
- Mills AA, "p53: link to the past, bridge to the future", Genes Dev, 19, pp.2091~2099 (2005)[DOI]
- Traverso G, "Detection of APC mutations in fecal DNA from patients with colorectal tumors", N Engl J Med, 346, pp.311~320 (2002)[DOI]
- Imperiale TF, "Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population", N Engl J Med, 351, pp.2704~2714 (2004)[DOI]
- Simmer F, "Comparative genomewide DNA methylation analysis of colorectal tumor and matched normal tissues", Epigenetics, 7, pp.1355~1367 (2012)[DOI]
- Warton K, "Methylation of cell-free circulating DNA in the diagnosis of cancer", Front Mol Biosci, 2, pp.13~ (2015)
- Hinoue T, "Genome-scale analysis of aberrant DNA methylation in colorectal cancer", Genome Res, 22, pp.271~282 (2012)[DOI]
- 강기주, "The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer", Gut and Liver, 9(2), pp.202~207 (2015), 거트앤리버 소화기연관학회협의회
- Su XL, "High methylation of the SEPT9 gene in Chinese colorectal cancer patients", Genet Mol Res, 13, pp.2513~2520 (2014)[DOI]
- Vedeld HM, "The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers", Int J Cancer, 136, pp.844~853 (2015)[DOI]
- Vedeld HM, "The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer", Epigenetics, 9, pp.346~350 (2014)[DOI]
- Xu Y, "Unique DNA methylome profiles in CpG island methylator phenotype colon cancers", Genome Res, 22, pp.283~291 (2012)[DOI]
- Imperiale TF, "Multitarget stool DNA testing for colorectal-cancer screening", N Engl J Med, 370, pp.1287~1297 (2014)[DOI]
- Park H, "Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells", J Biol Chem, 277, pp.29730~29736 (2002)[DOI]